US2008096937A1PendingUtilityA1
Novel hexafluoroisopropanol derivatives
Est. expiryJun 28, 2024(expired)· nominal 20-yr term from priority
A61P 3/06A61P 43/00A61P 3/10A61P 9/10A61P 25/28A61P 27/02A61P 3/00A61P 29/00C07D 277/28C07C 215/68A61P 1/18A61P 17/00A61P 1/16C07D 333/58A61P 1/00C07D 263/32C07D 213/38
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein R 1 to R 6 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.
Claims
exact text as granted — not AI-modified1 . A compound of the formula (I):
wherein:
R 1 is hydrogen, halogen, or lower-alkyl;
R 2 is lower-alkyl, fluoro-lower-alkyl, cycloalkyl-lower-alkyl, or heterocyclyl-lower-alkyl;
R 3 is hydrogen, lower-alkyl, aryl, cycloalkyl, or heterocyclyl;
R 4 is hydrogen, hydroxy, lower-alkoxy, aryl-lower-alkoxy, or heterocyclyl-lower-alkoxy;
R 5 is hydrogen, lower-alkyl, aryl, or heterocyclyl;
R 6 is aryl or heterocyclyl;
m is 0 to 3;
n is 0 or 1;
and pharmaceutically acceptable salts and esters thereof.
2 . The compound according to claim 1 , wherein R 1 is hydrogen or halogen.
3 . The compound according to claim 1 , wherein R 1 is hydrogen or chlorine.
4 . The compound according to claim 1 , wherein R 2 is lower-alkyl or fluoro-lower-alkyl.
5 . The compound according to claim 1 , wherein R 2 is ethyl or 2,2,2-trifluoro-ethyl.
6 . The compound according to claim 1 , wherein R 3 is hydrogen or aryl.
7 . The compound according to claim 1 , wherein R 3 is hydrogen or phenyl.
8 . The compound according to claim 1 , wherein R 3 is hydrogen.
9 . The compound according to claim 1 , wherein R 4 is hydrogen or hydroxy.
10 . The compound according to claim 1 , wherein R 5 is hydrogen.
11 . The compound according to claim 1 , wherein R 6 is phenyl, pyridinyl, thiazolyl, or benzo[b]thiophenyl, which is optionally substituted with halogen.
12 . The compound according to claim 1 , wherein R 6 is phenyl, chloro-phenyl, pyridinyl, thiazolyl, or chloro-benzo[b]thiophenyl.
13 . The compound according to claim 1 , wherein R 6 is phenyl.
14 . The compound according to claim 1 , wherein m is 0 to 2.
15 . The compound according to claim 1 , wherein m is 0.
16 . The compound according to claim 1 , wherein n is 0.
17 . The compound according to claim 1 , selected from the group consisting of:
2-[4-(Benzyl-ethyl-amino)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[(2-Chloro-benzyl)-ethyl-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[(3-Chloro-benzyl)-ethyl-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[(4-Chloro-benzyl)-ethyl-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-[4-(Ethyl-phenethyl-amino)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-[4-(Benzhydryl-ethyl-amino)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[ethyl-(thiazol-4-ylmethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[ethyl-(pyridin-2-ylmethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[ethyl-(pyridin-3-ylmethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[ethyl-(pyridin-4-ylmethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[Benzyl-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[(5-Chloro-benzo[b]thiophen-2-ylmethyl)-(2,2,2-trifluoro-ethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[Ethyl-(2-hydroxy-2-phenyl-ethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, (R) 2-{4-[Ethyl-(2-hydroxy-2-phenyl-ethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, (S) 2-{4-[Ethyl-(2-hydroxy-2-phenyl-ethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, (R) 2-(4-{[2-(3-Chloro-phenyl)-2-hydroxy-ethyl]-ethyl-amino}-phenyl)-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-[4-(Benzyl-ethyl-amino)-3-chloro-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{3-chloro-4-[ethyl-(thiazol-4-ylmethyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{4-[Benzyl-(2,2,2-trifluoro-ethyl)-amino]-3-chloro-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, 2-{3-Chloro-4-[ethyl-(3-phenyl-propyl)-amino]-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, and 2-[3-Chloro-4-(ethyl-phenethyl-amino)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol, and pharmaceutically acceptable salts and esters thereof.
18 . The compound according to claim 1 , selected from the group consisting of:
2-[4-(Benzyl-ethyl-amino)-3-chloro-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol, and 2-{4-[Benzyl-(2,2,2-trifluoro-ethyl)-amino]-3-chloro-phenyl}-1,1,1,3,3,3-hexafluoro-propan-2-ol, and pharmaceutically acceptable salts and esters thereof.
19 . A process for the manufacture of compounds of formula (I) as defined in claim 1 , comprising the step of:
a) reacting a compound of formula (II):
with a compound LG-CHR 3 —(CH 2 ) m —(CR 4 R 5 ) n —R 6 , or
b) reacting a compound of formula (III):
with a compound LG-R 2 ,
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m and n are as defined in any of claims 1 - 23 and LG is a leaving group.
20 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier and/or adjuvant.
21 . A method for the treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, comprising the step of administering a therapeutically effective amount of a compound according to claim 1 to a human being or animal in need thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.